JP2014139220A5 - - Google Patents

Download PDF

Info

Publication number
JP2014139220A5
JP2014139220A5 JP2014061763A JP2014061763A JP2014139220A5 JP 2014139220 A5 JP2014139220 A5 JP 2014139220A5 JP 2014061763 A JP2014061763 A JP 2014061763A JP 2014061763 A JP2014061763 A JP 2014061763A JP 2014139220 A5 JP2014139220 A5 JP 2014139220A5
Authority
JP
Japan
Prior art keywords
patient
drug
administered
parathyroid hormone
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014061763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014139220A (ja
JP6177718B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014139220A publication Critical patent/JP2014139220A/ja
Publication of JP2014139220A5 publication Critical patent/JP2014139220A5/ja
Application granted granted Critical
Publication of JP6177718B2 publication Critical patent/JP6177718B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2014061763A 1998-08-19 2014-03-25 骨の靭性、及び、剛性を増し、骨折を減少させる方法 Expired - Lifetime JP6177718B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US60/097,151 1998-08-19
US9974698P 1998-09-10 1998-09-10
US60/099,746 1998-09-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010244314A Division JP2011021035A (ja) 1998-08-19 2010-10-29 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014204577A Division JP2015028065A (ja) 1998-08-19 2014-10-03 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Publications (3)

Publication Number Publication Date
JP2014139220A JP2014139220A (ja) 2014-07-31
JP2014139220A5 true JP2014139220A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-09-25
JP6177718B2 JP6177718B2 (ja) 2017-08-09

Family

ID=26792729

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000565916A Pending JP2002523375A (ja) 1998-08-19 1999-08-19 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2010244314A Withdrawn JP2011021035A (ja) 1998-08-19 2010-10-29 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2014061763A Expired - Lifetime JP6177718B2 (ja) 1998-08-19 2014-03-25 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2014204577A Withdrawn JP2015028065A (ja) 1998-08-19 2014-10-03 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2017124301A Withdrawn JP2017190332A (ja) 1998-08-19 2017-06-26 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000565916A Pending JP2002523375A (ja) 1998-08-19 1999-08-19 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2010244314A Withdrawn JP2011021035A (ja) 1998-08-19 2010-10-29 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014204577A Withdrawn JP2015028065A (ja) 1998-08-19 2014-10-03 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2017124301A Withdrawn JP2017190332A (ja) 1998-08-19 2017-06-26 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Country Status (32)

Country Link
US (2) US6977077B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP2907522B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (5) JP2002523375A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100454207B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1205997C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR033639A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE231000T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU746277B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9909445A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2325371C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5130020A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1113343T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ301017B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE69904918T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (4) DK1769804T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DZ (1) DZ2873A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA003362B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (4) ES2393200T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20000755A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU1200430D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID29039A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL138829A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY129227A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO323984B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ507056A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20001089A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL201688B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (4) PT1059933E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200003455T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW576747B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA72205C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000010596A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
EP1222465A1 (en) * 1999-09-20 2002-07-17 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
AU2003207512B2 (en) * 2002-01-10 2008-06-12 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
RU2006108557A (ru) * 2003-09-19 2007-09-27 Пфайзер Продактс Инк. (Us) Фармацевтические композиции, включающие в себя сочетания производных 2-алкилиден-19-нор-витамина d и паратиреоидного гормона, и способы (лечения)
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
EP1750756A2 (en) * 2004-05-10 2007-02-14 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
ES2568259T3 (es) 2004-05-13 2016-04-28 Alza Corporation Aparato y método para la administración transdérmica de agentes de hormona paratiroidea
WO2006124062A1 (en) * 2005-05-11 2006-11-23 Unigene Laboratories, Inc. Method for fostering bone formation and preservation
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
WO2008125655A1 (en) 2007-04-13 2008-10-23 Kuros Biosurgery Ag Polymeric tissue sealant
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
WO2009072119A2 (en) * 2007-12-04 2009-06-11 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic peptide matrices for treatment of osteoporosis
EP2227263A2 (en) 2007-12-28 2010-09-15 Kuros Biosurgery AG Pdgf fusion proteins incorporated into fibrin foams
ES2843649T3 (es) 2009-09-09 2021-07-20 Asahi Kasei Pharma Corp Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
ES2761635T3 (es) 2011-06-07 2020-05-20 Asahi Kasei Pharma Corp Preparación liofilizada que contiene PTH de alta pureza y método para producirla
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2017136195A1 (en) 2016-02-01 2017-08-10 Eli Lilly And Company Parathyroid hormone – anti-rankl antibody fusion compounds
US20190381341A1 (en) * 2017-02-01 2019-12-19 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
CN110996988A (zh) * 2017-09-22 2020-04-10 旭化成制药株式会社 稳定性优异的含有特立帕肽的液态药物组合物
CN111447943A (zh) 2018-10-29 2020-07-24 旭化成制药株式会社 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法
JP7684951B2 (ja) 2019-08-09 2025-05-28 フラッグシップ・パイオニアリング・イノベーションズ・ブイアイ,エルエルシー 副甲状腺ホルモン受容体(pthr1)の調節剤
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
EP0800405A4 (en) * 1994-12-19 1998-11-11 Beth Israel Hospital CONTINUOUS LOW-DOSE ADMINISTRATION OF PARATHYROIDHORMONE OR THEIR AGONIST
HU218940B (hu) * 1994-12-22 2001-01-29 Astra Aktiebolag Paratiroid hormont (PHT) tartalmazó, inhalációs célra szolgáló gyógyszerkészítmény, eljárás előállítására, alkalmazása inhalációs készülék töltésére és ezt tartalmazó inhalációs készülék
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
IL134719A0 (en) * 1997-09-09 2001-04-30 Hoffmann La Roche FRACTURE HEALING USING PTHrP ANALOGS
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Similar Documents

Publication Publication Date Title
JP2014139220A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
JP2017533972A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
NZ617397A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
EP4410295A3 (en) Use of vibegron to treat overactive bladder
JP2016509050A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
RU2020120156A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена
JP2019529569A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
EP4389218A3 (en) Composition for treating joint disease and kit containing same
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
MX2019014201A (es) Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas.
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
MX2018013477A (es) Acidos carboxilicos para tratar/prevenir una enfermedad de la piel.